Results 241 to 250 of about 359,969 (268)

Cernilton for benign prostatic hyperplasia

Cochrane Database of Systematic Reviews, 1998
Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily.
T, Wilt, R, Mac Donald, A, Ishani, I, Rutks, G, Stark   +4 more
openaire   +2 more sources

Terazosin for benign prostatic hyperplasia

Cochrane Database of Systematic Reviews, 2000
Lower urinary tract symptoms associated with benign prostatic obstruction (BPO) occur in up to 70% of men over the age of 60 years. To relieve these bothersome symptoms, treatment options include alpha-antagonists, also know as alpha-blockers.We conducted a systematic review to evaluate the effectiveness and adverse effects of the alpha-blocker ...
T J, Wilt, R W, Howe, I R, Rutks, R, MacDonald   +3 more
openaire   +2 more sources

MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA

Annual Review of Medicine, 1997
▪ Abstract  Benign prostatic hyperplasia (BPH) is a common cause of morbidity among older men. Primary care physicians need to develop expertise in its management. The causes of BPH are unknown; aging and the presence of male androgens are the dominant risk factors.
M, Barry, C, Roehrborn
openaire   +2 more sources

Pathogenesis of Benign Prostatic Hyperplasia

European Urology, 1991
The pathogenesis of benign prostatic hyperplasia (BPH) remains largely unresolved. Three major theories have evolved over the years, each emphasizing a possible causative mechanism. The first theory, the dihydrotestosterone hypothesis, is based on the failure of BPH to develop in men castrated prior to puberty.
openaire   +2 more sources

Investigation of benign prostatic hyperplasia

Current Opinion in Urology, 2003
This is a concise and timely update of the most recent developments in the clinical research on the investigation of benign prostatic hyperplasia.Analysis of the peer-review literature confirms a high level of consensus as to the management of prostatic hyperplasia; analysis of practice trends suggests a satisfactory degree of adoption of the proposed ...
TUBARO, ANDREA, TRUCCHI, Alberto, MIANO, Lucio   +2 more
openaire   +3 more sources

Management of Benign Prostatic Hyperplasia

Annual Review of Medicine, 2016
Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development.
Eric H, Kim, Jeffrey A, Larson, Gerald L, Andriole   +2 more
openaire   +2 more sources

Herbs for Benign Prostatic Hyperplasia

Annals of Pharmacotherapy, 2002
OBJECTIVE: To review and evaluate the literature relative to the use of herbal therapies in the treatment of benign prostatic hyperplasia. DATA SOURCES: Literature was identified by MEDLINE, Embase, International Pharmaceutical ...
Lana, Dvorkin, Kathy Y, Song
openaire   +2 more sources

Tadalafil for benign prostatic hyperplasia

Drug and Therapeutics Bulletin, 2013
Tadalafil is a phosphodiesterase type-5 (PDE5) inhibitor licensed for the treatment of erectile dysfunction (ED) in adult males (Cialis—Lilly) and for the management of pulmonary arterial hypertension (Adcirca—Lilly).1 The 5mg tablet was licensed in November 2012 for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult
openaire   +2 more sources

Nutrition and benign prostatic hyperplasia

Current Opinion in Urology, 2013
Nutrition seems to modify the pathogenesis of benign prostatic hyperplasia (BPH) effect symptomology in men suffering from lower urinary tract symptoms (LUTS). Although there are numerous pharmaceuticals and procedures for these conditions, nutrition may improve outcomes as a primary approach or in tandem with BPH medications or procedures. The purpose
openaire   +2 more sources

Pathophysiology of Benign Prostatic Hyperplasia

European Urology, 1994
The exact morphogenesis of benign prostatic hyperplasia (BPH) is unknown, but morphologic observations and different etiologic theories, such as the stem cell, dihydrotestosterone, and stromal-epithelial interaction hypotheses, help to explain some of the findings. For example, the initial changes in the development of BPH may result from an activation
openaire   +2 more sources